{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T21:06:34Z","timestamp":1768770394406,"version":"3.49.0"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2014,2,24]],"date-time":"2014-02-24T00:00:00Z","timestamp":1393200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/3.0\/"},{"start":{"date-parts":[[2014,2,24]],"date-time":"2014-02-24T00:00:00Z","timestamp":1393200000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/3.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>This study establishes a proof-of-concept that a tattoo device can target intra-dermal drug delivery against cutaneous leishmaniasis (CL). The selected drug is oleylphosphocholine (OlPC) formulated as liposomes, particles known to be prone to macrophage ingestion. We first show that treatment of cultured <jats:italic>Leishmania<\/jats:italic>-infected macrophages with OlPC-liposomes results in a direct dose-dependent killing of intracellular parasites. Based on this, <jats:italic>in vivo<\/jats:italic> efficacy is demonstrated using a 10 day tattooing-mediated treatment in mice infected with <jats:italic>L. major<\/jats:italic> and <jats:italic>L. mexicana<\/jats:italic>. In both models this regimen results in rapid clinical recovery with complete regression of skin lesions by Day 28. Parasite counts and histopathology examination confirm high treatment efficacy at the parasitic level. Low amount of drug required for tattooing combined with fast clinical recovery may have a positive impact on CL patient management. This first example of tattoo-mediated drug delivery could open to new therapeutic interventions in the treatment of skin diseases.<\/jats:p>","DOI":"10.1038\/srep04156","type":"journal-article","created":{"date-parts":[[2014,2,24]],"date-time":"2014-02-24T10:31:03Z","timestamp":1393237863000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Drug Delivery by Tattooing to Treat Cutaneous Leishmaniasis"],"prefix":"10.1038","volume":"4","author":[{"given":"Marina Temi","family":"Shio","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marilene","family":"Paquet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caroline","family":"Martel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tom","family":"Bosschaerts","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stef","family":"Stienstra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Olivier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anny","family":"Fortin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,2,24]]},"reference":[{"key":"BFsrep04156_CR1","unstructured":"WHO technical report series; no. 949. Control of the leishmaniases. Report of a meeting of the WHO Expert Committee on the Control of Leishmaniases, Geneva, 22\u201326 March 2010; \u00a9 World Health Organization, 2010; WHO Press, Switzerland. http:\/\/whqlibdoc.who.int\/trs\/WHO_TRS_949_eng.pdf (accessed on 23\/05\/2012)."},{"key":"BFsrep04156_CR2","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1517\/17425247.2012.701204","volume":"9","author":"G Carneiro","year":"2012","unstructured":"Carneiro, G., Aguiar, M. G., Fernandes, A. P. & Ferreira, L. A. Drug delivery systems for the topical treatment of cutaneous leishmaniasis. Expert. Opin. Drug Deliv. 9, 1083\u20131097 (2012).","journal-title":"Expert. Opin. Drug Deliv."},{"key":"BFsrep04156_CR3","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1038\/nm1264","volume":"11","author":"AD Bins","year":"2005","unstructured":"Bins, A. D. et al. A rapid and potent DNA vaccination strategy defined by in vivo monitoring of antigen expression. Nat. Med. 11, 899\u2013904 (2005).","journal-title":"Nat. Med."},{"key":"BFsrep04156_CR4","doi-asserted-by":"publisher","first-page":"2707","DOI":"10.1093\/jac\/dks273","volume":"67","author":"A Fortin","year":"2012","unstructured":"Fortin, A. et al. Efficacy and tolerability of oleylphosphocholine (OlPC) in a laboratory model of visceral leishmaniasis. J. Antimicrob. Chemother. 67, 2707\u20132712 (2012).","journal-title":"J. Antimicrob. Chemother."},{"key":"BFsrep04156_CR5","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.taap.2005.04.003","volume":"209","author":"NV Gopee","year":"2005","unstructured":"Gopee, N. V. et al. Response of mouse skin to tattooing: use of SKH-1 mice as a surrogate model for human tattooing. Toxicol. Appl. Pharmacol. 209, 145\u2013158 (2005).","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"BFsrep04156_CR6","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/1479-0556-6-4","volume":"6","author":"D Pokorna","year":"2008","unstructured":"Pokorna, D., Rubio, I. & Muller, M. DNA-vaccination via tattooing induces stronger humoral and cellular immune responses than intramuscular delivery supported by molecular adjuvants. Genet. Vaccines. Ther. 6, 4 (2008).","journal-title":"Genet. Vaccines. Ther."},{"key":"BFsrep04156_CR7","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1517\/17425247.5.7.805","volume":"5","author":"EL Romero","year":"2008","unstructured":"Romero, E. L. & Morilla, M. J. Drug delivery systems against leishmaniasis? Still an open question. Expert. Opin. Drug Deliv. 5, 805\u2013823 (2008).","journal-title":"Expert. Opin. Drug Deliv."},{"key":"BFsrep04156_CR8","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1111\/j.1365-3156.2006.01782.x","volume":"12","author":"V Vanlerberghe","year":"2007","unstructured":"Vanlerberghe, V. et al. Drug policy for visceral leishmaniasis: a cost-effectiveness analysis. Trop. Med. Int. Health 12, 274\u2013283 (2007).","journal-title":"Trop. Med. Int. Health"},{"key":"BFsrep04156_CR9","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1128\/AAC.50.2.474-479.2006","volume":"50","author":"S St George","year":"2006","unstructured":"St George, S. et al. Novel compounds active against Leishmania major. Antimicrob. Agents Chemother. 50, 474\u2013479 (2006).","journal-title":"Antimicrob. Agents Chemother."},{"key":"BFsrep04156_CR10","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1002\/jlb.50.3.263","volume":"50","author":"D Radzioch","year":"1991","unstructured":"Radzioch, D. et al. Genetic resistance\/susceptibility to mycobacteria: phenotypic expression in bone marrow derived macrophage lines. J. Leukoc. Biol. 50, 263\u2013272 (1991).","journal-title":"J. Leukoc. Biol."},{"key":"BFsrep04156_CR11","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/S0166-6851(00)00270-X","volume":"110","author":"G Roy","year":"2000","unstructured":"Roy, G. et al. Episomal and stable expression of the luciferase reporter gene for quantifying Leishmania spp. infections in macrophages and in animal models. Mol. Biochem. Parasitol. 110, 195\u2013206 (2000).","journal-title":"Mol. Biochem. Parasitol."},{"key":"BFsrep04156_CR12","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/S0169-4758(96)40010-2","volume":"13","author":"HC Lima","year":"1997","unstructured":"Lima, H. C., Bleyenberg, J. A. & Titus, R. G. A simple method for quantifying Leishmania in tissues of infected animals. Parasitol. Today 13, 80\u201382 (1997).","journal-title":"Parasitol. Today"},{"key":"BFsrep04156_CR13","doi-asserted-by":"publisher","first-page":"ra58","DOI":"10.1126\/scisignal.2000213","volume":"2","author":"MA Gomez","year":"2009","unstructured":"Gomez, M. A. et al. Leishmania GP63 alters host signaling through cleavage-activated protein tyrosine phosphatases. Sci. Signal. 2, ra58 (2009).","journal-title":"Sci. Signal."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/srep04156.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep04156","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep04156.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,6]],"date-time":"2023-01-06T08:59:52Z","timestamp":1672995592000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/srep04156"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,2,24]]},"references-count":13,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2014,12,17]]}},"alternative-id":["BFsrep04156"],"URL":"https:\/\/doi.org\/10.1038\/srep04156","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,2,24]]},"assertion":[{"value":"19 November 2013","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2014","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2014","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"S.S. is a member of the scientific advisory board of MT-Derm and Amiea, receiving financial compensations. A.F. is a consultant for Dafra Pharma R&D. T.B. is an employee of Dafra Pharma R&D. All other authors declare no potential conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"4156"}}